Journal Watch · Blood · 2026
CD28+ CD8+ Tem cells with a STAT1-dependent glucocorticoid receptor deficit contribute to steroid-refractory acute GVHD.
CD28+ CD8+ Tem cell counts may serve as a biomarker of SR-aGVHD and inform the development of preemptive, pathway-targeted therapeutic strategies.
TL;DR
CD28+ CD8+ Tem cell counts may serve as a biomarker of SR-aGVHD and inform the development of preemptive, pathway-targeted therapeutic strategies.
Key findings
- Single-cell RNA sequencing and functional assays implicated a STAT1-glucocorticoid receptor (GR) regulatory axis, in which inflammatory cytokines induce STAT1 phosphorylation and suppress GR expression, consistent with intrinsic glucocorticoid resistance.
- JAK inhibition rescued cytokine-induced steroid resistance in vitro, whereas in patients with SR-aGVHD, clinical response to ruxolitinib was accompanied by reduced STAT1 activation, restoration of GR expression, and contraction of the expanded CD8+ Tem cell pool.
- These findings identify immune dysregulation in SR-aGVHD centered on CD8+ Tem cells with a STAT1-dependent GR deficit and support a mechanistic link to steroid refractoriness.
- CD28+ CD8+ Tem cell counts may serve as a biomarker of SR-aGVHD and inform the development of preemptive, pathway-targeted therapeutic strategies.
What they did
Mass cytometry revealed an expansion of activated CD28+ CD8+ effector-memory T (Tem) cells in SR-aGVHD. Absolute counts of these cells at neutrophil engraftment predicted subsequent steroid resistance in the multicenter cohort and performed comparably to established clinical classifiers. This phenotype was associated with a proinflammatory milieu enriched in interleukin-2 (IL-2), IL-27, and interferon gamma.
Full abstract (original)
Background: <h4>Abstract</h4>Steroid-refractory (SR) disease develops in a substantial fraction of patients with grade II to IV acute graft-versus-host disease (aGVHD) and is associated with poor long-term survival. Improved mechanistic insight is needed to identify reliable predictors of steroid resistance. We retrospectively profiled peripheral blood collected before glucocorticoid treatment from allogeneic hematopoietic cell transplantation recipients without aGVHD, with steroid-sensitive aGVHD, and with SR-aGVHD using an integrated multiomics approach, and validated our findings in an independent multicenter cohort.
What they did: Mass cytometry revealed an expansion of activated CD28+ CD8+ effector-memory T (Tem) cells in SR-aGVHD. Absolute counts of these cells at neutrophil engraftment predicted subsequent steroid resistance in the multicenter cohort and performed comparably to established clinical classifiers. This phenotype was associated with a proinflammatory milieu enriched in interleukin-2 (IL-2), IL-27, and interferon gamma.
Results & conclusions: Single-cell RNA sequencing and functional assays implicated a STAT1-glucocorticoid receptor (GR) regulatory axis, in which inflammatory cytokines induce STAT1 phosphorylation and suppress GR expression, consistent with intrinsic glucocorticoid resistance. JAK inhibition rescued cytokine-induced steroid resistance in vitro, whereas in patients with SR-aGVHD, clinical response to ruxolitinib was accompanied by reduced STAT1 activation, restoration of GR expression, and contraction of the expanded CD8+ Tem cell pool. These findings identify immune dysregulation in SR-aGVHD centered on CD8+ Tem cells with a STAT1-dependent GR deficit and support a mechanistic link to steroid refractoriness. CD28+ CD8+ Tem cell counts may serve as a biomarker of SR-aGVHD and inform the development of preemptive, pathway-targeted therapeutic strategies.
Abstract © the authors / Blood (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1182/blood.2025032587 · PubMed 41980031.
Why it matters for pharma & biotech
- Relevant to Immunology teams tracking Blood for new targets, mechanisms and biomarkers.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Blood study find?
CD28+ CD8+ Tem cell counts may serve as a biomarker of SR-aGVHD and inform the development of preemptive, pathway-targeted therapeutic strategies.
What type of study is this?
It is a cohort / observational clinical study, published in Blood in 2026. Mass cytometry revealed an expansion of activated CD28+ CD8+ effector-memory T (Tem) cells in SR-aGVHD.
Where can I read the original paper?
The original is at the publisher via DOI 10.1182/blood.2025032587. PubMed ID: 41980031. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/cd28-cd8-tem-cells-with-a-stat1-dependent-glucocorticoid-receptor-defici-032587/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides